Tech Center 1600 • Art Units: 1632 1633
This examiner grants 70% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18467089 | Blood Plasma Product | Non-Final OA | Velico Medical, Inc. |
| 17767822 | STEM CELL-DERIVED MATURE CARDIOMYOCYTES AND CARDIOVASCULAR DISEASE MODEL USING SAME | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17766762 | DAUGHTERLESS MALE MAMMALS FOR NON-HUMAN POPULATION SUPPRESSION | Non-Final OA | Massachusetts Institute of Technology |
| 17156492 | Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing | Final Rejection | Massachusetts Institute of Technology |
| 18026482 | CELL-SUPPORTING BODY, MANUFACTURING METHOD THEREFOR, CELL CULTURING METHOD, AND CELL STRUCTURE | Final Rejection | Konica Minolta, Inc. |
| 18460022 | METHODS AND COMPOSITIONS FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS | Non-Final OA | Cambridge Enterprise Limited |
| 18019931 | PLATFORM VECTOR FOR MODULAR AND SIMPLIFIED INSERTION OF TRANSGENES INTO ALPHAHERPESVIRINAE | Final Rejection | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. |
| 18246872 | COMPOSITIONS AND METHODS FOR TREATMENT OF FABRY DISEASE | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17787161 | 3D TISSUE COMPOSITE AND METHOD OF PRODUCING 3D TISSUE COMPOSITE | Non-Final OA | The University Of Tokyo |
| 17779505 | NOVEL AAV3B VARIANTS THAT TARGET HUMAN HEPATOCYTES IN THE LIVER OF HUMANIZED MICE | Non-Final OA | University of Massachusetts |
| 17794087 | LIPID NANOPARTICLES COMPRISING LESS THAN 1 MOL% OF A C18-PEG LIPID | Non-Final OA | VRIJE UNIVERSITEIT BRUSSEL |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | Non-Final OA | ASKBIO INC. |
| 17796303 | Process for Making Adenoassociated Viral Vectors | Final Rejection | Oxford University Innovation Limited |
| 18011089 | COMPOSITIONS AND METHODS FOR REGULATING ENTEROENDOCRINE CELL DIFFERENTIATION AND USES THEREOF | Final Rejection | The Children's Medical Center Corporation |
| 18044047 | MINIATURIZED CYTIDINE DEAMINASE-CONTAINING COMPLEX FOR MODIFYING DOUBLE-STRANDED DNA | Final Rejection | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY |
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | Final Rejection | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | Final Rejection | CRISPR Therapeutics AG |
| 17280003 | MESENCHYMAL STEM CELLS DERIVED FROM SYNOVIUM AND USES THEREOF | Non-Final OA | INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18575031 | PHARMACEUTICAL COMPOSITION CONTAINING IRRADIATED HEMATOPOIETIC STEM CELLS | Non-Final OA | JAPANESE RED CROSS SOCIETY |
| 17897857 | PROMOTER OF THE TRANSCRIPTION OF NUCLEIC ACID SEQUENCE AN ITS USE | Final Rejection | UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO |
| 18363663 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA | Non-Final OA | Astellas Institute for Regenerative Medicine |
| 17587973 | ANTITUMOR IMMUNITY ENHANCING COMPOSITION CONTAINING ADENOVIRUS SIMULTANEOUSLY EXPRESSING IL-12 AND SHVEGF | Final Rejection | Genemedicine Co., Ltd. |
| 17773426 | METHOD FOR TARGETED MODIFICATION OF SEQUENCE OF PLANT GENOME | Non-Final OA | SUZHOU QI BIODESIGN BIOTECHNOLOGY COMPANY LIMITED |
| 17779458 | METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES | Non-Final OA | KSQ Therapeutics, Inc. |
| 18366539 | PREVENTION OF SPACE TRAVEL ASSOCIATED BONE DENSITY LOSS BY REGENERATIVE CELL POPULATIONS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18273891 | CELL STRAIN FOR PRODUCING BIOSIMILAR DRUG OF USTEKINUMAB AND PRODUCTION METHOD THEREFOR | Non-Final OA | QYUNS THERAPEUTICS CO., LTD. |
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | Final Rejection | National Institute of Biological Sciences, Beijing |
| 18258502 | MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY | Non-Final OA | PRIME VECTOR TECHNOLOGIES GMBH |
| 18255182 | COMPOSITIONS AND METHODS FOR THE TARGETING OF PTBP1 | Non-Final OA | Scribe Therapeutics Inc. |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | Non-Final OA | Astellas Gene Therapies, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy